Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 224

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Anal Cancer Risk Among People With HIV Infection in the United States

Open access
Colón-López, Vivian, Shiels, Meredith S., Machin, Mark, Ortiz, Ana P., Strickler, Howard, Castle, Philip E., Pfeiffer, Ruth M., Engels, Eric A. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: People with HIV infection have an elevated risk of anal cancer. However, recent calendar trends are incompletely described, and which population subgroups might benefit from cancer screening is unknown. Methods: We used linked data from HIV and cancer registries in nine US areas (1996 to 2012). We calculated standardized incidence ratios to compare anal cancer incidence in people with HIV infection with the general population, used Poisson regression to evaluate anal cancer incidence among subgroups of people with HIV and to assess temporal trends, and estimated the cumulative incidence of anal cancer to measure absolute risk. Results: Among 447,953 people with HIV infection, anal cancer incidence was much higher than in the general population (standardized incidence ratio, 19.1; 95% CI, 18.1 to 20.0). Anal cancer incidence was highest among men who have sex with men (MSM), increased with age, and was higher in people with AIDS than in those without AIDS (ie, HIV only; adjusted incidence rate ratio, 3.82; 95% CI, 3.27 to 4.46). Incidence among people with HIV increased steeply during 1996 to 2000 (annual percentage change, 32.8%; 95% CI, −1.0% to 78.2%), reached a plateau during 2001 to 2008, and declined during 2008 to 2012 (annual percentage change, −7.2%; 95% CI, −14.4% to 0.6%). Cumulative incidence after a 5-year period was high for MSM with HIV only age 45 to 59 or ≥ 60 years (0.32% to 0.33%) and MSM with AIDS age 30 to 44, 45 to 59, or ≥ 60 years (0.29% to 0.65%). Conclusion: Anal cancer incidence is markedly elevated among people with HIV infection, especially in MSM, older individuals, and people with AIDS. Recent declines may reflect delayed benefits of HIV treatment. Groups with high cumulative incidence of anal cancer may benefit from screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.9291

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • HIV infection, immunosuppression, and age at diagnosis of non-AIDS-defining cancers

    Shiels, M. S., Althoff, K. N., Pfeiffer, R. M., Achenbach, C. J., Abraham, A. G., Castilho, J., Cescon, A., D’Souza, G., Dubrow, R., Eron, J. J., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw764 · Cited by 95 · cited 1×

    “Among these individuals, a low CD4 count is associatedwith an increased risk of anal cancer,(12,13) and immunosuppression seems most important at early stages in the development of anal cancer.(14) Although anal cancer incidence did not clearly decline during the first decade of the HAARTera, a lag might have been pos…”
    BackgroundSelf-citation

Cited by

See all 224

Metadata

Authors
Colón-López, V., Shiels, M. S., Machin, M., Ortiz, A. P., Strickler, H., Castle, P. E., Pfeiffer, R. M., & Engels, E. A.
Venue
Journal of Clinical Oncology
Published
2018-01-01
Volume
36
Issue
1
Pages
68-75
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2769055533
Cited by
224
References
1
FWCI
16.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.